Publication & Citation Trends
Publications
0 total
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI‐Atrial Fibrillation Trial OA
Cited by 77
Semantic Scholar
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Cited by 1,088
Semantic Scholar
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Cited by 1,014
Semantic Scholar
Coffee Consumption and Risk of Cardiovascular Events After Acute Myocardial Infarction
Cited by 5
Semantic Scholar
Starc II, a multicenter randomized placebo‐controlled double‐blind clinical trial of trapidil for 1‐year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting
Cited by 15
Semantic Scholar
Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) OA
Cited by 46
Semantic Scholar
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. OA
Cited by 37
Semantic Scholar
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. OA
Cited by 446
Semantic Scholar
Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI-2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell-Infarto Mioc
Cited by 58
Semantic Scholar
Research Topics
Heart Failure Treatment and Management
(527)
Cardiovascular Function and Risk Factors
(338)
Atrial Fibrillation Management and Outcomes
(216)
Cardiac pacing and defibrillation studies
(175)
Acute Myocardial Infarction Research
(163)
Affiliations
Université Claude Bernard Lyon 1
University of Siena
AstraZeneca (United Kingdom)
Université de Tours
Délégation Paris 5